Thursday, 13 November 2014

Hoorah! 1st MSer recruited into the PROXIMUS study yesterday

I'm happy to report that we screened the first MSer into the study yesterday. We had celebratory drinks yesterday to mark the landmark event!!

The concept took off the ground in 2010 off the back of PROMISE 2010, funded by the National Multiple Sclerosis Society (NMSS).  Four years down the line, after obtaining the funding, sponser approval, hiring the staff, obtaining regulatory approval, producing the tablets, and setting up the trial measures, we're finally there!



4 comments:

  1. Please can you remind us what the trial is testing and when it is likely to report. Thanks.

    ReplyDelete
    Replies
    1. The trial details are NCT02104661 (Clinical Trials. gov) Protective Role of Oxcarbazepine in Multiple Sclerosis (PROXIMUS).

      Estimated finish time will now be May 2016

      Delete
  2. There must be some way to expedite this process. I'm guessing this is a Phase 1 or Phase 2 study. So 6 years after Promise 2010 we will have some results. If positive a Phase 3 trial will be need. Then licensing - although it may end up like Simvastin! So if all goes to plan the drug might get a licence in 2020! Good job this isn't a serious disease. Don't get me wrong, I'm grateful for all the effort. Just wish I''d got MS 20 years later.

    ReplyDelete
    Replies
    1. Money! Funding for research is being cut, but the cost of doing a clinical trial is going up and up. We can just about do a Phase II study but not Phase III - I refer to the MS-STAT trial.

      Delete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.